Business

AuraVax Therapeutics, which is developing an intranasal vaccine against COVID-19, announced that it has acquired an exclusive license for IP related to intranasal respiratory vaccine technology and STING agonist technology from the University of Houston. Earlier this year, the company announced that it had licensed liposomal STING agonist technology from Massachusetts … [Read more...] about AuraVax licenses intranasal vaccine technology from University of Houston

Revelation Biosciences said that it has closed a private placement financing with gross proceeds of $4.4 million that it plans to use for development of two pipeline products, including its REVTx-99 intranasal phosphorylated hexaacylated disaccharide (PHAD). REVTx-99 is in development for the treatment of viral respiratory infections, including COVID-19.  In … [Read more...] about Revelation Biosciences raises $4.4 million for development of REVTx‑99 intranasal PHAD

According to Pulmotect, the US Department of Defense has provided a grant worth up to $6 million for the completion of two Phase-2 clinical trials of the company's PUL-042 immunostimulant inhalation solution for the prevention and treatment of COVID-19. In May 2020, Pulmotect announced that it had gotten FDA permission for the two trials. The studies, which both … [Read more...] about US Department of Defense provides up to $6 million for Phase 2 trials of PUL-042 inhalation solution for the treatment of COVID-19

University of St Andrews spin out Pneumagen said that it has raised £2.5 million for clinical development of its Neumifil intranasal carbohydrate binding module (mCBM) for the prevention and treatment of respiratory viruses, including flu, RSV, and COVID-19. The company says that it previously raised £4 million investment for development of Neumifil, which is … [Read more...] about Pneumagen raises £2.5 million for clinical development of Neumifil nasal spray against flu, RSV, and COVID-19

Odyssey Group International said that it has signed a definitive agreement with Prevacus to acquire PRV-002, an intranasal therapy for the treatment of mild traumatic brain injury. As part of the deal, Prevacus CEO Jake Vanlandingham will join Odyssey. In 2017, Prevacus announced that it planned to initiate a Phase 1 trial of PRV-002; however, Prevacus has been … [Read more...] about Odyssey acquired intranasal therapy for the treatment of mild traumatic brain injury from Prevacus

Intranasal vaccine developer AuraVax Therapeutics said that the company has licensed liposomal STING agonist technology from Massachusetts General Hospital (MGH) for use as an adjuvant in vaccines against COVID-19 and other respiratory diseases. The technology was developed by MGH researcher Mei X. Wu. AuraVax co-founder Navin Varadarajan commented, "We are … [Read more...] about AuraVax Therapeutics licences intranasal vaccine adjuvant technology from Massachusetts General Hospital

Catalent will pay Acorda Therapeutics $80 million cash for Acorda's manufacturing operations in Chelsea, MA, USA where the company makes Inbrija dry powder levodopa. According to Catalent, the 90,000 sq ft CGMP facility "will act as a global center of excellence within the Catalent network for spray-dried dispersion and dry powder encapsulation and … [Read more...] about Acorda sells Inbrija manufacturing operations to Catalent